BioSpace News Archive

Verastem, Inc. announced an oral presentation highlighting supportive Phase 1 clinical data for duvelisib in patients with relapsed or refractory peripheral T-cell lymphoma at the 2019 International Conference on Malignant Lymphoma being held June 18-22, 2019, in Lugano, Switzerland.

The DIA 2019 Global Annual Meeting will host more than 7,000 professionals in the pharmaceutical, biotechnology, and medical device communities as well as 400 exhibiting companies, including AMPLEXOR.

Epizyme, Inc. reported positive interim data from an ongoing Phase 2 trial of its lead candidate, tazemetostat, as a monotherapy for patients with relapsed or refractory follicular lymphoma who have received at least two prior lines of systemic therapy.

IsoPlexis, a company focused on advancing single-cell functional biomarkers to address critical challenges in oncology & beyond, today announced that it has received $4 million in grant funding from the National Cancer Institute’s Small Business Innovation Research

In an ongoing effort to rationalize their store footprint, Fred’s Inc., has once again tapped SB360 Capital Partners, one of North America’s leading asset disposition specialists, as the exclusive consultant to conduct “Store Closing” Sales in 49 additional stores.

The Emergency Nurses Association and ITN Productions announced Friday a partnership to produce a news and current affairs-style program designed to raise awareness about the importance of injury prevention initiatives as part of the effort to reduce preventable injuries and deaths.

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today presented new preclinical data showing preserved bone health with edasalonexent in contrast to negative effects of the corticosteroid prednisolone in a mouse model of Duchenne muscular dystrophy (DMD)

SOFIE Inc. (SOFIE), a Theranostics company, is pleased to announce an exclusive global license with University Clinic Heidelberg (UKHD) for a class of molecular targeted diagnostics and radiotherapeutics (“theranostics”) that are designed to identify and break down cancer associated fibroblasts in tumor stroma and irradiate nearby cancer cells.

ACT uses an unconventional approach to create awareness around anonymous HIV testing. 51% of people living with HIV in Canada are gay or bisexual men.

Mӧlnlycke® will celebrate the game-changing invention of Safetac® technology while focusing on continued innovations in wound care at WOCNext 2019 being held June 23-26 in Nashville, TN.